Blood, the flagship journal of the American Society of Hematology, published online and in print, provides an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology. Acceptance of manuscripts is based on the originality and importance of the observations or investigations, the quality of the work and validity of the evidence, the clarity of presentation, and the relevance to our readership and field. All articles are expected to be concise, well-organized and clearly written. Authors submit a manuscript with the understanding that the manuscript (or its essential substance) has not been published other than as an abstract in any language or format and is not currently submitted elsewhere for print or electronic publication.
Primary research articles will be published under the following scientific categories: Clinical Trials and Observations; Gene Therapy; Hematopoiesis and Stem Cells; Immunobiology and Immunotherapy; Myeloid Neoplasia; Lymphoid Neoplasia; Phagocytes, Granulocytes and Myelopoiesis; Platelets and Thrombopoiesis; Red Cells, Iron and Erythropoiesis; Thrombosis and Hemostasis; Transfusion Medicine; Transplantation; and Vascular Biology. Papers can be listed under more than one category as appropriate. Authors are invited to submit a presubmission inquiry if they are uncertain whether their work falls within the general scope of the journal.
Blood has formulated more precise scopes for immunobiology and immunotherapy, vascular biology, HIV/HTLV, and clinical trial submissions. The journal is very interested in submissions as reflected in the definitions linked below.
Blood welcomes submission of manuscripts reporting on clinical trials whether phase 1, 2, 3 or 4. Reports should include a full description of the study design, patient population, methodology and conduct, and statistical plan.
Immunobiology and Immunotherapy encompass a wide spectrum of research, but Blood can accommodate only papers that have clear and important implications for hematology. Preference is given to papers focusing on human immunobiology, immunotherapy, and immune pharmacology approaches in the human setting and those with significant implications for understanding of normal or malignant hematologic processes. Papers on tumor immunology, tumor vaccines and cancer immunotherapy development may be appropriate if the target cells or antigens are relevant to hematologic malignancies, but generally Blood cannot accommodate tumor immunology papers focusing solely on non-hematologic tumor types.
Papers investigating autoimmunity and utilizing non-hematologic models are not within the scope of Blood.
Vascular biology papers that focus primarily on atherosclerosis are outside the scope of Blood and instead should be considered for alternative journals.
Papers felt to be outside the scope of Blood will be returned to the author without full peer review.
Blood, the flagship journal of the American Society of Hematology, published online and in print, provides an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology. Acceptance of manuscripts is based on …
With more than 18,000 members from nearly 100 countries, the American Society of Hematology is the world's largest professional society serving both clinicians and scientists around the world who are working to conquer blood diseases.
